TLDR:
- Pan Cancer T, a biotech startup in the Netherlands, raised €4.25M in Seed extension funding.
- The funding will be used for preclinical studies, progress CMC activities, and support pipeline projects.
A Rotterdam-based biotech startup, Pan Cancer T, has secured €4.25M in Seed extension funding. The round was led by InnovationQuarter and included participation from existing investors such as Van Herk Ventures, Thuja Capital, Swanbridge Capital, and Erasmus MC O&O Holdings. The total amount raised by the company now stands at approximately €11M. Nina Satih from InnovationQuarter will take on a Supervisory Board observer role as a result of this funding.
Pan Cancer T plans to use the funds to complete preclinical studies for its lead TCR-T cell product, PCT1:CO-STIM, and progress CMC activities to create value and derisk the project. The funding will also support the advancement of earlier-stage pipeline projects targeting colorectal and ovarian cancers, as well as the development of a second next-generation engineering approach.
Founded in late 2020 as a spin-off from Erasmus MC, Pan Cancer T is focused on developing TCR T cell therapies for hard-to-treat solid tumors. The company’s approach includes targeting unique T cell markers that are exclusively expressed by multiple solid cancers and developing technologies to enhance the durability of T cells. Their lead clinical candidate, PCT1:CO-STIM, targets a novel tumor-restricted marker called ROPN1, which is highly expressed in patients with triple negative breast cancer and melanoma.
Overall, Pan Cancer T’s funding will support the advancement of their innovative T cell therapies and pipeline projects, with a focus on addressing hard-to-treat solid tumors and improving patient outcomes.
